TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05893888: A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Sponsor: Privo Technologies · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,521,828

Rescue Site Savings

+$1,014,552

Unlock Full NCT05893888 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05893888 Rescue Dossier →